SCHEMBL2149785

SCHEMBL2149785

CC(CI)NCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8061118 0.80 TDP1 (0.43)
SCHEMBL18743786 0.79
SCHEMBL10207609 0.78
SCHEMBL10207613 0.78
SCHEMBL2556696 0.78
SCHEMBL1581176 0.78
SCHEMBL164712 0.78
SCHEMBL13774332 0.78
SCHEMBL22290525 0.76
SCHEMBL16267280 0.76 MME (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122768-A2 T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES Yeda Research and Development Co. Ltd. (IL) 2017-02-01 EP disclosed
WO-2015145449-A2 T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2015-10-01 WO disclosed
EP-2342334-A1 TUMOR VASCULAR MARKER-TARGETED VACCINES The Trustees Of The University Of Pennsylvania (US) 2011-07-13 EP disclosed
WO-2010037124-A1 TUMOR VASCULAR MARKER-TARGETED VACCINES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-04-01 WO disclosed
WO-2010019995-A1 THE ERG TRANSCRIPTION FACTOR MODULATION OF VASCULAR DEVELOPMENT THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2010-02-25 WO disclosed
EP-2091967-A1 CRYSTALLINE COMPOSITION OF GM-CSF/GM-CSFR St. Vincent's Institute of Medical Research (AU) 2009-08-26 EP disclosed
EP-1844069-A4 MOLECULES AND CHIMERIC MOLECULES THEREOF APOLLO LIFE SCIENCES LTD (AU) 2009-05-20 EP disclosed
EP-1910535-A4 THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME INST MEDICAL W & E HALL (AU) 2009-05-20 EP disclosed
WO-2008086573-A1 USE OF GALANIN IN A METHOD OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2008-07-24 WO disclosed
WO-2008077194-A1 RECEPTOR AGONISTS XENOME LTD (AU) 2008-07-03 WO disclosed
WO-2007025347-A1 PROPHYLACTIC AND THERAPEUTIC AGENTS AND USES THEREFOR HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2007-03-08 WO disclosed
WO-2006135985-A1 THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2006-12-28 WO disclosed
WO-2006129320-A2 BIODEGRADABLE POLYMERS HAVING A PRE-DETERMINED CHIRALITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-12-07 WO disclosed
WO-2006122363-A1 THERAPEUTIC AGENTS AND TARGETS AUTOGEN RESEARCH PTY LTD (AU) 2006-11-23 WO disclosed
WO-2006108211-A1 FRAGMENTS OF VON WILLEBRAND FACTOR A-RELATED PROTEIN THE MURDOCH CHILDRENS RESEARCH INSTITUTE (AU) 2006-10-19 WO disclosed
WO-2006079176-A1 MOLECULES AND CHIMERIC MOLECULES THEREOF APOLLO LIFE SCIENCES LIMITED (AU) 2006-08-03 WO disclosed
WO-2006060871-A1 BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND (AU) 2006-06-15 WO disclosed
WO-2006029462-A1 A NUCLEIC ACID MOLECULE DIFFERENTIALLY EXPRESSED IN A MOUSE BEHAVIOURAL MODEL SYSTEM AND USES THEREOF AUTOGEN RESEARCH PTY LTD (AU) 2006-03-23 WO disclosed
WO-2006026820-A1 TREATING GLIOSIS, GLIAL SCARRING, INFLAMMATION OR INHIBITION OF AXONAL GROWTH IN THE NERVOUS SYSTEM BY MODULATING EPH RECEPTOR THE UNIVERSITY OF QUEENSLAND (AU) 2006-03-16 WO disclosed
WO-2006007667-A1 THERAPEUTIC AND DIAGNOSTIC AGENTS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2006-01-26 WO disclosed